Skip to main content

Cytokine Release Syndrome

4
Pipeline Programs
6
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 5 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Incyte
IncyteDE - Wilmington
1 program
1
ItacitinibPhase 2Small Molecule1 trial
Active Trials
NCT04071366Completed112Est. Aug 2023
CytoAgents
CytoAgentsPA - Pittsburgh
1 program
1
CTO1681 10 μgPhase 1/21 trial
Active Trials
NCT05905328Recruiting54Est. Jun 2027
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
ST266Phase 11 trial
Active Trials
NCT04720378Completed12Est. May 2022
Noveome Biotherapeutics
1 program
1
ST266Phase 1
CytoSorbents
CytoSorbentsPRINCETON, NJ
1 program
CytosorbN/A1 trial
Active Trials
NCT04048434Unknown34Est. Sep 2024
IQVIA
IQVIADURHAM, NC
1 program
ST266PHASE_1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
IncyteItacitinib
CytoAgentsCTO1681 10 μg
BioTherapeutics IncST266
CytoSorbentsCytosorb

Clinical Trials (4)

Total enrollment: 212 patients across 4 trials

NCT04071366IncyteItacitinib

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Start: Feb 2020Est. completion: Aug 2023112 patients
Phase 2Completed
NCT05905328CytoAgentsCTO1681 10 μg

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

Start: Dec 2023Est. completion: Jun 202754 patients
Phase 1/2Recruiting
NCT04720378BioTherapeutics IncST266

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

Start: May 2021Est. completion: May 202212 patients
Phase 1Completed
NCT04048434CytoSorbentsCytosorb

Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)

Start: Jun 2021Est. completion: Sep 202434 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 212 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.